Systemic Glucocorticoid Immunosuppression and Survival Among Immune Checkpoint Inhibitor Recipients - Takeaways - MDSpire

Systemic Glucocorticoid Immunosuppression and Survival Among Immune Checkpoint Inhibitor Recipients

  • By

  • Guihong Wan

  • Nga Nguyen

  • Charles Lu

  • Sara Khattab

  • Boshen Yan

  • Munachimso Amadife

  • Bonnie W. Leung

  • Wenxin Chen

  • Ahmad Rajeh

  • Kimberly Tang

  • Christopher Thang

  • Genevieve Boland

  • Kerry L. Reynolds

  • Kun-Hsing Yu

  • Alexander Gusev

  • Nicole R. LeBoeuf

  • Shawn G. Kwatra

  • Yevgeniy R. Semenov

  • May 22, 2026

  • 0 min

Share

  • 1

    Systemic glucocorticoid immunosuppression (gsISP) is commonly used among patients receiving immune checkpoint inhibitors (ICIs) for various indications.

  • 2

    A meta-analysis indicated that higher corticosteroid doses for managing immune-related adverse events (irAEs) were linked to poorer survival in ICI recipients.

  • 3

    The study utilized a large multi-institutional cohort to examine the impact of gsISP on overall survival among cancer patients treated with ICIs.

  • 4

    The research included two cohorts: one from Massachusetts General Hospital and another from a US population-based TriNetX network.

  • 5

    The study aimed to clarify the associations of gsISP timing, dose, and duration with overall survival across multiple cancer types.

Original Source(s)

Systemic Glucocorticoid Immunosuppression and Survival Among Immune Checkpoint Inhibitor Recipients

  • by Guihong Wan, Nga Nguyen, Charles Lu, Sara Khattab, Boshen Yan, Munachimso Amadife, Bonnie W. Leung, Wenxin Chen, Ahmad Rajeh, Kimberly Tang, Christopher Thang, Genevieve Boland, Kerry L. Reynolds, Kun-Hsing Yu, Alexander Gusev, Nicole R. LeBoeuf, Shawn G. Kwatra, Yevgeniy R. Semenov

  • May 22, 2026

Related Content

Artificial intelligence for optimization of immunotherapy: current applications and transformative potential

Recurrent pleuropulmonary blastoma type III initially misclassified as embryonal rhabdomyosarcoma on limited biopsy: a case report with pathogenic DICER1 variant

Myelodysplastic syndromes complicated by atypical Sweet syndrome: a brief research report